Brookfield Asset Management Inc
Change company Symbol lookup
Select an option...
BAM Brookfield Asset Management Inc
XOM Exxon Mobil Corp
NEWR New Relic Inc
T AT&T Inc
AICAF Air China Ltd
MMM 3M Co
JNJ Johnson & Johnson
TIP iShares TIPS Bond ETF
OCUL Ocular Therapeutix Inc
NLY Annaly Capital Management Inc
Go

Financials : Capital Markets | Large Cap Blend
Based in Canada
Company profile

Brookfield Asset Management Inc. is an alternative asset manager. Its operations are organized into its seven operating segments. Asset management operations include managing its listed partnerships (LP), private funds and public securities on behalf of its investors. Real estate operations include the ownership, operation and development of core office, core retail, LP investments and other properties. Renewable power operations include the ownership, operation and development of hydroelectric, wind, solar, storage and other power generating facilities. Infrastructure operations include the ownership, operation and development of utilities, transport, energy, data infrastructure and sustainable resource assets. Private equity operations include a broad range of industries and are mostly focused on business services, infrastructure services and industrials. Residential development operations consist of homebuilding, condominium development and land development.

Postmarket

Last Trade
Delayed
$32.90
-0.0138 (-0.04%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$32.91
Day's Change
-0.55 (-1.64%)
Bid
--
Ask
--
B/A Size
--
Day's High
33.45
Day's Low
32.66
Volume
(Heavy Day)
Volume:
2,399,606

10-day average volume:
1,897,083
2,399,606

NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment

9:11 am ET August 7, 2020 (MarketWatch)
Print

The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s (GILD) remdesivir with Merck KGaA's interferon beta-1a as a treatment for COVID-19 patients. The study plans to enroll 1,000 people who have been hospitalized because of a COVID-19 infection. The federal agency said it expects to have preliminary results in the fall. Since the Food and Drug Administration granted an emergency use authorization to remdesivir in May, several clinical trials have been initiated that aim to pair the investigational therapy with other drugs to see if the combination can better treat severely ill COVID-19 patients. This includes another NIH trial (http://www.marketwatch.com/story/government-to-test-remdesivir-with-lilly-drug-in-covid-19-patients-2020-05-08) pairing remdesivir with Eli Lilly & Co. (LLY) and Incyte Corp. (INCY)'s Olumiant. Roche Holding AG has also said it will test (http://www.marketwatch.com/story/roches-shares-rise-on-news-of-study-testing-actemra-remdesivir-in-covid-19-patients-2020-05-28) its rheumatoid arthritis drug in combination with remdesivir.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

August 07, 2020 09:11 ET (13:11 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.